Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib
about
Melanoma and the Unfolded Protein ResponseGetting TRAIL back on track for cancer therapyRecognition of Smac-mimetic compounds by the BIR domain of cIAP1Structural Insight into Inhibitor of Apoptosis Proteins Recognition by a Potent Divalent Smac-MimeticThe Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancerA small molecule SMAC mimic LBW242 potentiates TRAIL- and anticancer drug-mediated cell death of ovarian cancer cellsConjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancerInducing death in tumor cells: roles of the inhibitor of apoptosis proteins.HtrA1 sensitizes ovarian cancer cells to cisplatin-induced cytotoxicity by targeting XIAP for degradation.EGFR-targeted TRAIL and a Smac mimetic synergize to overcome apoptosis resistance in KRAS mutant colorectal cancer cells.Progesterone receptor-B induction of BIRC3 protects endometrial cancer cells from AP1-59-mediated apoptosis.Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathwaysA promising "TRAIL" of tanshinones for cancer therapy.Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity.IAP antagonists sensitize murine osteosarcoma cells to killing by TNFαInhibitor of apoptosis proteins: fascinating biology leads to attractive tumor therapeutic targets.Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspectsTowards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review).The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.Combination therapy of antiandrogen and XIAP inhibitor for treating advanced prostate cancer.NF-κB inducing kinase (NIK) modulates melanoma tumorigenesis by regulating expression of pro-survival factors through the β-catenin pathway.Smac mimetic compounds potentiate interleukin-1beta-mediated cell deathSensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonist.Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms.Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway.LPS promotes resistance to TRAIL-induced apoptosis in pancreatic cancerCLL cells are resistant to smac mimetics because of an inability to form a ripoptosome complex.The plant alkaloid and anti-leukemia drug homoharringtonine sensitizes resistant human colorectal carcinoma cells to TRAIL-induced apoptosis via multiple mechanisms.Negative correlation between X-linked inhibitors of apoptosis and second mitochondria-derived activator of caspase expression levels in cervical carcinoma and cervical intraepithelial neoplasia.Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy.Inhibitor of apoptosis proteins, NAIP, cIAP1 and cIAP2 expression during macrophage differentiation and M1/M2 polarization.Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma
P2860
Q26765426-8CC6EAC5-95FD-4373-8B10-AD2477AFE43DQ27027460-CA154F1E-9E0E-4586-90FE-E0922E9ABECEQ27665119-11587F60-6B24-40B0-BA03-5F01DC40F7CCQ27675179-51EFF303-8B25-4F15-B4DA-8469D18E3A1EQ28468300-898BAB3D-0796-4AFB-8ED2-9D6B655AE594Q28482952-BFD15825-F6B0-418D-AADB-36A03DF2147EQ33589984-B5128232-BA0D-417B-916A-17CBB1397D1BQ33632016-03185F31-05DC-441A-B070-6B17796F1BA8Q33841141-30CC43FD-A9DB-498E-A71C-CE9C438FFEF6Q34149887-EB38654D-5F7B-4CB8-93C1-528DC8B2EF7BQ35097256-9115B1C2-EFB9-4602-BF29-4B81B60308D5Q36184769-32DDB8B8-C98B-49DE-85BF-21CCD3E933D0Q36332681-D169D6E8-CC03-4E8B-80E6-1FAF966BBCE3Q37357090-1ACF91ED-4E12-43C8-8495-861ACF8B2356Q37376164-2F470D11-F1CB-4345-9491-010971E2FC50Q37875078-AA9EC7AE-C278-4587-8FCD-AE6DA2084F17Q37948056-AB362E56-9D08-4BDC-9B99-BF2FC3241473Q38219616-0A8B0250-A0D7-408A-8129-86B0FD15F18BQ39195579-629CBDAF-5F9B-4EC8-A10E-17C5F8016906Q39373427-423C4380-B972-41B5-93EA-8D18F788B435Q39464868-613ABC83-9822-4811-B448-4DD11C3E9DBFQ39642704-D8ECA545-CB03-4462-B199-A1B1F7651085Q39664088-CC14BDBA-697A-49A0-8774-9E540AC899EFQ40071126-2D335FB3-6355-457B-9A4E-E3A4FF7093F3Q41627000-8B493CAF-2A09-412F-96DC-7EC81C2B183EQ41949682-E0B682D0-4F9C-4502-85B5-8E2469307C0AQ42585598-C60DD0E0-51FC-4A04-BAEE-F91ACB7FA15FQ43468001-0048AA35-C9CD-4071-84AC-058D16EE5832Q45684338-1454C24D-FF49-4AE1-95D6-AE460D70064FQ51746852-E652591F-E85B-450B-A6A6-C60DA3A4A6FCQ52666797-51F59C79-7EEB-4802-9173-6BB5E29EDB0CQ58700213-7D4CF591-F484-4591-8B38-7239BDA7F5D0
P2860
Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Novel SMAC-mimetics synergisti ...... tion with TRAIL and Bortezomib
@ast
Novel SMAC-mimetics synergisti ...... tion with TRAIL and Bortezomib
@en
type
label
Novel SMAC-mimetics synergisti ...... tion with TRAIL and Bortezomib
@ast
Novel SMAC-mimetics synergisti ...... tion with TRAIL and Bortezomib
@en
prefLabel
Novel SMAC-mimetics synergisti ...... tion with TRAIL and Bortezomib
@ast
Novel SMAC-mimetics synergisti ...... tion with TRAIL and Bortezomib
@en
P2093
P2860
P50
P356
P1476
Novel SMAC-mimetics synergisti ...... tion with TRAIL and Bortezomib
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605687
P407
P577
2010-05-11T00:00:00Z
P5875
P6179
1049467437